ICH Meets in Estonia - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ICH Meets in Estonia


ePT--the Electronic Newsletter of Pharmaceutical Technology

Last week, the steering committee and expert working groups (EWGs) of the International Conference on Harmonizaton (ICH) met in Tallinn, Estonia, to discuss progress on the ICH quality trio guidelines and other Step-4 documents.

The ICH Quality Implementation Working Group, which focuses on guidelines Q8 Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System, held its first training workshop during the meeting. The workshop focused on how to use design space, control strategy, and quality risk management, among other topics. Approximately 240 individuals, including inspectors, from 34 countries attended the workshop. Additional workshops will be held in Washington, DC, and in Tokyo, in October 2010.

ICH representatives also adopted Annexes 11 and 12 to the Q4B guideline titled Evaluation and Recommendation of Pharmacopoeial Text for Use in the ICH Regions to Step 4. The next phase, Step 5, requires each region to publish and implement the guideline. The annexes harmonize analytical procedures for capillary electrophoresis and sieving. Two additional Q4B annexes, Annex 13 on bulk and tapped density and Annex 14 on bacterial endotoxin, moved to Step 2, which means the six parties to ICH have reached consensus on a draft guideline.

Also of note, the Q3D EWG held its first official meeting to set limits on metal impurities in drug products and ingredients. The group has been working with pharmacopoeias around the world on this controversial industry topic. The working group is not expected to address specific tests for heavy metals.

Two new EWGs were formed to focus on genotoxic impurities and photosafety evaluation.

The next ICH meeting of the steering committee and EWGs will be held in Japan in November 2010.

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here